The Food and Drug Administration (FDA) has submitted draft CBD enforcement guidance to the White House Office of Management and Budget (OMB) for review.
The contents or even basic scope of the document—titled, “Cannabidiol Enforcement Policy; Draft Guidance for Industry”—are not yet publicly known.
The agency was mandated under appropriations legislation passed late last year to provide an update on its regulatory approach to CBD, and it did so in March. The update stated that “FDA is currently evaluating issuance of a risk-based enforcement policy that would provide greater transparency and clarity regarding factors FDA intends to take into account in prioritizing enforcement decisions.”
FDA Commissioner Stephen Hahn said when that report was submitted to Congress that “any enforcement policy would need to further the goals of protecting the public and providing more clarity to industry and the public regarding the FDA’s enforcement priorities while we take potential steps to establish a clear regulatory pathway.”
